181 related articles for article (PubMed ID: 33426708)
21. L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine.
Wang R; Shao M
Ann Palliat Med; 2020 May; 9(3):947-956. PubMed ID: 32279520
[TBL] [Abstract][Full Text] [Related]
22. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Lipari N; Centner A; Glinski J; Cohen S; Manfredsson FP; Bishop C
Neurobiol Dis; 2023 Jan; 176():105965. PubMed ID: 36526089
[TBL] [Abstract][Full Text] [Related]
23. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
24. Effects of Muscarinic Acetylcholine m1 and m4 Receptor Blockade on Dyskinesia in the Hemi-Parkinsonian Rat.
Chambers NE; Meadows SM; Taylor A; Sheena E; Lanza K; Conti MM; Bishop C
Neuroscience; 2019 Jun; 409():180-194. PubMed ID: 31029732
[TBL] [Abstract][Full Text] [Related]
25. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
26. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
27. Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
Conti MM; Goldenberg AA; Kuberka A; Mohamed M; Eissa S; Lindenbach D; Bishop C
Pharmacol Biochem Behav; 2016 Mar; 142():64-71. PubMed ID: 26791104
[TBL] [Abstract][Full Text] [Related]
28. Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.
Elson JL; Kochaj R; Reynolds R; Pienaar IS
Neurotox Res; 2018 Jul; 34(1):16-31. PubMed ID: 29218504
[TBL] [Abstract][Full Text] [Related]
29. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
[TBL] [Abstract][Full Text] [Related]
30. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
31. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC
Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107
[TBL] [Abstract][Full Text] [Related]
32. The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.
Aristieta A; Azkona G; Sagarduy A; Miguelez C; Ruiz-Ortega JÁ; Sanchez-Pernaute R; Ugedo L
PLoS One; 2012; 7(8):e42652. PubMed ID: 22880070
[TBL] [Abstract][Full Text] [Related]
33. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Dupre KB; Eskow KL; Negron G; Bishop C
Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
[TBL] [Abstract][Full Text] [Related]
34. Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Marin C; Bonastre M; Fuentes M; Mullol J
Pharmacol Biochem Behav; 2020 Oct; 197():173013. PubMed ID: 32758524
[TBL] [Abstract][Full Text] [Related]
35. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
36. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
Albarrán-Bravo S; Ávalos-Fuentes JA; Cortés H; Rodriguez-Sánchez M; Leyva-García N; Rangel-Barajas C; Erlij D; Florán B
Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480516
[TBL] [Abstract][Full Text] [Related]
37. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Chotibut T; Meadows S; Kasanga EA; McInnis T; Cantu MA; Bishop C; Salvatore MF
Mov Disord; 2017 Nov; 32(11):1547-1556. PubMed ID: 28631864
[TBL] [Abstract][Full Text] [Related]
38. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
[TBL] [Abstract][Full Text] [Related]
39. Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems.
Grabli D; Karachi C; Folgoas E; Monfort M; Tande D; Clark S; Civelli O; Hirsch EC; François C
J Neurosci; 2013 Jul; 33(29):11986-93. PubMed ID: 23864685
[TBL] [Abstract][Full Text] [Related]
40. Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Wang T; Duan SJ; Wang SY; Lu Y; Zhu Q; Wang LJ; Han B
Physiol Behav; 2015 Aug; 147():193-7. PubMed ID: 25914172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
